^
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR expression-Colorectal Cancer-cetuximab]

    Source:
    FDA
    Test:

    Dako EGFR pharmDx™

    Published date:
    11/10/2020
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:...Colorectal Cancer: K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test...in combination with FOLFIRI for first-line treatment…in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy… as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
    Secondary therapy:
    irinotecan
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR expression-Colorectal Cancer-cetuximab]

    Source:
    FDA
    Test:

    Dako EGFR pharmDx™

    Published date:
    11/10/2020
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:...Colorectal Cancer: K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test...in combination with FOLFIRI for first-line treatment…in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy… as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: C3 – Early Trials

    [EGFR expression-Colorectal Cancer-cetuximab]

    Source:
    J Clin Oncol
    Test:

    Dako EGFR pharmDx™

    Title:
    Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
    Excerpt:
    Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation...Patients were required to have received irinotecan...Cetuximab was administered weekly by intravenous infusion...Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses.
    DOI:
    10.1200/JCO.2004.10.182